Blueprint Medicines Income Statement

Financials in millions USD. Fiscal year is July - June.

Millions USD. Fiscal year is Jul - Jun.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar '25 Mar 31, 2025	Jun '24 Jun 30, 2024	Jun '23 Jun 30, 2023	Jun '22 Jun 30, 2022	Jun '21 Jun 30, 2021	Jun '20 Jun 30, 2020
Revenue	974.67	959.27	851.5	653.49	81.81	584.6
Revenue Growth (YoY)	5.81%	12.66%	30.30%	698.77%	-86.00%	-
Cost of Revenue	534.24	547.05	478.85	394.79	75.85	360.28
Gross Profit	440.43	412.22	372.64	258.7	5.96	224.33
Selling, General & Admin	236.1	232.19	204.71	188.79	157.24	159.58
Operating Expenses	292.34	286.07	265.17	258.33	228.82	241.17
Operating Income	148.09	126.15	107.47	0.37	-222.86	-16.84
Interest Expense	-52.99	-57.95	-51.87	-53.11	-33.74	-0.43
Interest & Investment Income	2.15	2.98	7.24	7.15	6.44	8.81
Other Non Operating Income (Expenses)	-0.59	0.01	0.95	-0.04	-0.3	0.89
EBT Excluding Unusual Items	96.65	71.18	63.79	-45.63	-250.45	-7.57
Merger & Restructuring Charges	-2.86	-17.65	-10.24	-5.17	-14.69	-
Gain (Loss) on Sale of Investments	-1.84	-1.24	19.86	-49.84	51.18	37.63
Gain (Loss) on Sale of Assets	-	-	4.36	-	-	240.78
Other Unusual Items	-	-	-	-35.63	-	-
Pretax Income	82.25	52.29	77.77	-136.27	-213.96	270.84
Income Tax Expense	-49.28	-92.01	1.73	-0.07	5.35	100.18
Earnings From Continuing Operations	131.54	144.3	76.04	-136.2	-219.31	170.66
Minority Interest in Earnings	-	-	0.55	2.86	0.69	1.07
Net Income	131.54	144.3	76.6	-133.34	-218.61	171.73
Net Income to Common	131.54	144.3	76.6	-133.34	-218.61	171.73
Net Income Growth	148.69%	88.39%	-	-	-	-
Shares Outstanding (Basic)	48	48	52	52	52	24
Shares Outstanding (Diluted)	48	49	52	52	52	24
Shares Change (YoY)	-3.70%	-7.06%	0.98%	-	115.53%	-
EPS (Basic)	2.75	2.99	1.48	-2.58	-4.22	7.15
EPS (Diluted)	2.72	2.97	1.47	-2.58	-4.22	7.15
EPS Growth	157.00%	102.04%	-	-	-	-
Free Cash Flow	119.83	87.09	120.51	79.55	-158.43	1.88
Free Cash Flow Per Share	2.48	1.79	2.31	1.54	-3.06	0.08
Gross Margin	45.19%	42.97%	43.76%	39.59%	7.29%	38.37%
Operating Margin	15.19%	13.15%	12.62%	0.06%	-272.40%	-2.88%
Profit Margin	13.49%	15.04%	9.00%	-20.40%	-267.21%	29.38%
Free Cash Flow Margin	12.29%	9.08%	14.15%	12.17%	-193.66%	0.32%
EBITDA	204.33	180.02	167.94	69.9	-151.28	64.75
EBITDA Margin	20.96%	18.77%	19.72%	10.70%	-184.91%	11.08%
D&A For EBITDA	56.24	53.88	60.46	69.53	71.58	81.59
EBIT	148.09	126.15	107.47	0.37	-222.86	-16.84
EBIT Margin	15.19%	13.15%	12.62%	0.06%	-272.40%	-2.88%
Effective Tax Rate	-	-	2.22%	-	-	36.99%
Revenue as Reported	974.67	959.27	851.5	653.49	-	-
Advertising Expenses	-	11.03	8.83	8	0.27	10.9

Updated May 6, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q